Effectiveness of treatment for MDR TB in children and adolescents Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002
A study of prescription of second line drugs in chronic tuberculosis patients before confirmation of multi drug resistance bacteriologically Source: Annual Congress 2010 - Special treatment options in tuberculosis Year: 2010
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
The effectiveness of MDR TB treatment in children and adolescents depending on its duration Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012
The clinical features and treatment of cases with MDR TB of adolescents Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007
Results of traditional and new regimens of MDR/XDR TB treatment: cohort analysis Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019
The effectiveness and safety of empirical anti-TB therapy in a population with high TB prevalence Source: Eur Respir J 2001; 18: Suppl. 33, 468s Year: 2001
Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012
Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003
Outcome of drug resistant TB in hospital settings-a comparision of individualized treatment based on past history of anti-TB drugs with culture sensitivity guided treatment Source: Eur Respir J 2006; 28: Suppl. 50, 589s Year: 2006
The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007
Using results of drug sensitivity of infection source in initial chemotherapy choice in TB children and teenagers Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Preventive chemotherapy effectiveness in children and adolescents, contacting TB patients with DR TB strains Source: Eur Respir J 2006; 28: Suppl. 50, 536s Year: 2006
Individualized treatment regimens with second line anti-TB drugs (SLD) compared to first line anti-TB drug (FLD) only in new pulmonary TB patients, culture confirmed with full sensibility at drug sensibility test (DST) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007
Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003
Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR – TB in Iran Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012